Everybody, I hope you are all as well as can be and keeping warm it’s really taters in London today! Earlier in this thread I posted about contacting NICE on 24/11 with this question:
can someone please explain to me why NICE have authorised elective caesarians to be available to any woman who wants one but keep deferring the decision about NHS funding for Fingolimod? It would appear that NICE are happy to waste money for frivilous reasons on women ‘too posh to push’ but ignore the very genuine health needs of many who suffer from Multiple Sclerosis who could benefit from this important oral drug.
Thankyou for your attention.
Today I received their response:
Thank you for contacting the National Institute for Health and Clinical Excellence (NICE) and sharing your views with us.
NICE has recently updated our guidance on the topic of caesarean section. However, contrary to what you may have seen in the press, the guideline does not recommend that all women should be offered the option of a caesarean section. Rather, where a woman has a significant fear of childbirth, her anxiety may lead her to ask for a caesarean section. In such cases, the guideline says that she should be offered referral to a healthcare professional with expertise in providing support to talk through her fears and help her to address them. We know that this support can often help to allay women’s fears of childbirth sufficiently for them to be able to attempt a vaginal birth. But in some cases, the anxiety is not allayed and the women may feel that vaginal birth is not something she can face. In these circumstances she should be offered a planned caesarean section.
You can download the relevant guidance from the following pages of our website:
Caesarean section update: http://guidance.nice.org.uk/CG132
The shorter version of the guidance aimed at patients and carers may be of most interest to you: http://www.nice.org.uk/nicemedia/live/13620/57166/57166.pdf
If you have any questions arising from the recommendations made in this piece of guidance, please do not hesitate to contact us.
Fingolimod, for the treatment of relapsing-remitting multiple sclerosis, was referred to NICE in November 2008 and is due for publication in April 2012. Unfortunately, this technology appraisal was rescheduled in January 2010, July 2010 and February 2011. This was due to resource constraints and efficiency scheduling requirements and also, following advice from the manufacturer, to align with the latest regulatory expectations. Further information on this can be found on the relevant page of our website: http://guidance.nice.org.uk/TA/Wave20/71#schedule
I hope this information is useful to you.
Coordinator (Enquiry Handling)
National Institute for Health and Clinical Excellence
So I have responded:
Dear Ms Wallace,
thankyou for sharing the views of NICE with regard to authorising expensive elective caesarians. I too have a “significant fear” of my MS progressing and suffer much “anxiety” over it so on that basis I too should be able to choose which drug I can take. Your response does not address the question as to why NICE has refused to authorise Fingolimod to be funded by the NHS, perhaps you could now explain that for me? Thankyou.
Let’s see what they say this time.